A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates: Eastern Cooperative Oncology Group study E1E96
- 31 March 2004
- journal article
- clinical trial
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 92 (3), 957-964
- https://doi.org/10.1016/j.ygyno.2003.12.022
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI Journal of the National Cancer Institute, 1995
- Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specificJournal of General Virology, 1994
- Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones.The Journal of Experimental Medicine, 1994
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- Interleukin-12 Promotes the Proliferation and Cytolytic Maturation of Immune EffectorsJournal of Immunotherapy, 1993
- Recent Progress in Defining the Epidemiology of Human Papillomavirus Infection and Cervical NeoplasiaJNCI Journal of the National Cancer Institute, 1992
- Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammationProgress in Growth Factor Research, 1992
- The Human Papilloma Virus-16 E7 Oncoprotein Is Able to Bind to the Retinoblastoma Gene ProductScience, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958